About JOI
Junxin Oncology Institute is a 501(c)(3) non-profit research institute focused on radiation oncology innovation. Founded in 2026, JOI brings together leading oncologists, physicists, and researchers from top institutions across the US and China.
Our mission is to advance cancer treatment through innovative clinical research, with particular focus on:
SCART — Stereotactic Centralized Ablative Radiation Therapy
Adaptive radiation therapy that responds to anatomical changes during treatment.
SBRT — Stereotactic Body Radiation Therapy
High-precision, high-dose radiation delivery for extracranial tumors.
Radiation Immunity
Exploring the immune-modulating effects of radiation therapy.
Leadership
Baosheng Li, MD, PhD
President
Shandong Cancer Hospital
Board of Directors
Jun Yang, PhD, DABR
Chief Scientist
Junxin Oncology Group
Weisi Yan, MD, PhD
University of Kentucky
Liangfu Han, MD
Hainan Boao Evergrande
International Hospital
Research Faculty
Our team includes Principal Investigators from leading institutions:
United States
Youwen He, MD, PhD
Duke University
Cancer Immunotherapy
Rachelle Lanciano, MD
Delaware County Memorial Hospital
Gynecologic Cancer
John Lamond, MD
Pottstown Hospital
Radiation Oncology
Gary Li, MD
Radiation Oncology
Waleed Mourad, MD, MSc
University of Kentucky
Head & Neck Cancer
Dian Wang, MD
Radiation Oncology
Weisi Yan, MD, PhD
University of Kentucky
Radiation Oncology
Wei Song, MD
Phoenixville Hospital
Medical Oncology
China
Nianji Cui, MD
Sun Yat-sen University Cancer Center
Radiation Oncology
Liangfu Han, MD
Hainan Boao Evergrande Hospital
Full-service oncology, SBRT, SCART
Qiuxia Lu, MD
Foshan Chancheng Hospital
Radiotherapy, MDT
Weihua Qi, MSc
Chief Physicist
Junxin Medical
Enmin Wang, MD
Foshan CyberKnife Center
Neuro-radiosurgery
Yanming Wang, MD, PhD
PLA 960 Hospital
SABR/SBRT
Zhanjiang Yao
Junxin Medical
Hospital Management
Gang Ye, MD
Foshan Chancheng Hospital
Medical Oncology
Jiyuan Yang, MD
Junxin Oncology Hospital
Radiation Oncology
Qiu'an Yang, MD, PhD
Qilu Hospital, Shandong University
Full-service oncology, SBRT, SCART
Clinical Research Network
Affiliated Clinical Sites
| Site | Location | Capabilities |
|---|---|---|
| Jinan Junxin Cancer Hospital | Jinan, Shandong | Full-service oncology, SBRT, SCART |
| Foshan Chancheng Hospital Cancer Center | Foshan, Guangdong | CAR-T, Tumor Treating Fields, Full-service oncology, SBRT, SCART |
| Quanzhou Binhai Hospital International Cancer Center | Quanzhou, Fujian | Full-service oncology, SBRT, SCART |
| Shanghai Delta Health Cancer Center | Shanghai | Full-service oncology, SBRT, SCART |
| Nanjing Jiangbei Hospital Cancer Center | Nanjing, Jiangsu | Full-service oncology, SBRT, SCART |
| Beijing University Zibo LuZhong Hospital Cancer Center | Zibo, Shandong | Full-service oncology, SBRT, SCART |
| Fujian Zhangpu Tianfu Hospital Cancer Center | Zhangpu, Fujian | Full-service oncology, SBRT, SCART |
Ongoing Clinical Research
| Study | Phase | Sites | Focus |
|---|---|---|---|
| SCART vs CRT in Large Metastatic Cancers | Phase II Randomized | Foshan Chancheng Hospital | SCART innovation |
| Regional Nodal Irradiation in Breast Cancer | Phase III Multicenter | Multiple sites | Post-surgery RT |
| Early-Stage NSCLC SBRT | Phase II | 16 sites | Lung cancer SBRT |
| GBM Treatment | Phase II | 7 sites | Glioblastoma therapy |
Total Network: 49+ participating sites across China
Clinical Outcomes
Breast Cancer 5-Year Survival Rate Comparison
| Stage | JOI Network (China) | China Average | USA |
|---|---|---|---|
| 0 & I | 99.7% | ~95% | ~100% |
| II | 92.4% | ~85% | ~93% |
| III | 86.7% | ~70% | ~72% |
| IV | 35.2% | ~20% | ~28% |
Key Finding: Our clinical network achieves outcomes that match or exceed US standards across all stages, with particularly strong performance in advanced stages (III & IV), significantly outperforming both US and China national averages.
Technologies & Capabilities
Our clinical network has implemented advanced technologies:
| Technology | Status | Cases |
|---|---|---|
| SCART | International leading, Global first | 500+ |
| PET/CT Molecular Imaging | National leading | 10,000+ |
| SBRT Radiosurgery | National advanced, Local pioneering | 10,000+ |
| CyberKnife M6 | National leading, Regional pioneering | 1,000+ |
| Tumor Treating Fields | National leading, Local pioneering | 200+ |
| CAR-T Cell Therapy | National leading, Local pioneering | 10+ |